Immune modulation therapy (autoimmune disorders) - Vasogen

Drug Profile

Immune modulation therapy (autoimmune disorders) - Vasogen

Alternative Names: VAS 972

Latest Information Update: 23 Apr 2008

Price : $50

At a glance

  • Originator Vasogen
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 23 May 2003 Suspended - Phase-II for Psoriasis in Canada (Extracorporeal)
  • 23 May 2003 Suspended - Preclinical for Rheumatoid arthritis in Canada (Extracorporeal)
  • 22 Mar 2002 Data have been added to the Skin Disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top